Literature DB >> 31555697

Transplantation of umbilical cord mesenchymal stem cells into mice with focal segmental glomerulosclerosis delayed disease manifestation.

Yifan Shi1, Jingyuan Xie1, Mingxin Yang1, Jun Ma1, Hong Ren1.   

Abstract

BACKGROUND: Familial focal segmental glomerulosclerosis (fFSGS) is difficult to treat, and stem cell transplantation is one of the most promising approaches for treating this condition. According to the novel mutation site found in our FSGS family, we established a novel animal model of FSGS to explore the application of stem cell therapy in FSGS.
METHODS: The animal model used in this experiment was p.Gly1617Valfs X15 (C57BL/6) mutant mice. This mutation was first found in a focal segmental glomerulosclerosis (FSGS) family undergoing renal biopsy in our department. The mouse model was then constructed via CRISPR/Cas9 genomic editing technology. Then, the animals were injected with human umbilical cord mesenchymal stem cells (UCMSC) through the tail vein and regularly followed up to determine phenotypic changes in urine protein quantities, serum creatinine and histological outcomes.
RESULTS: Compared with the positive control group, the levels of urinary protein and serum creatine were decreased significantly after UCMSC transplantation. HE staining images revealed a delay in glomerular sclerosis. Moreover, the secretion of the type IV collagen α3 chain was significantly increased compared with the positive control group, as shown by using immunofluorescence microscopic observation, and electron microscopy proved that the podocytes and basement membrane recovered well from the damage. The intervention also resulted in enhanced IL-22 expression.
CONCLUSIONS: UCMSC transplantation may be a potential treatment for FSGS, and IL-22 may play an important role in this process. Further studies are needed to reveal the underlying mechanism.

Entities:  

Keywords:  Focal segmental glomerulosclerosis (FSGS); IL-22; animal model; stem cell therapy; type IV collagen

Year:  2019        PMID: 31555697      PMCID: PMC6736805          DOI: 10.21037/atm.2019.07.71

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  22 in total

Review 1.  Animal models of Alport syndrome: advancing the prospects for effective human gene therapy.

Authors:  P Heikkilä; K Tryggvason; P Thorner
Journal:  Exp Nephrol       Date:  2000 Jan-Feb

2.  Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease.

Authors:  Hikaru Sugimoto; Thomas M Mundel; Malin Sund; Liang Xie; Dominic Cosgrove; Raghu Kalluri
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-28       Impact factor: 11.205

3.  Chronic renal failure and shortened lifespan in COL4A3+/- mice: an animal model for thin basement membrane nephropathy.

Authors:  Bogdan Beirowski; Manfred Weber; Oliver Gross
Journal:  J Am Soc Nephrol       Date:  2006-06-14       Impact factor: 10.121

4.  Insertional mutation of the collagen genes Col4a3 and Col4a4 in a mouse model of Alport syndrome.

Authors:  W Lu; C L Phillips; P D Killen; T Hlaing; W R Harrison; F F Elder; J H Miner; P A Overbeek; M H Meisler
Journal:  Genomics       Date:  1999-10-15       Impact factor: 5.736

Review 5.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

6.  Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection.

Authors:  Dechun Feng; Xiaoni Kong; Honglei Weng; Ogyi Park; Hua Wang; Steven Dooley; M Eric Gershwin; Bin Gao
Journal:  Gastroenterology       Date:  2012-04-03       Impact factor: 22.682

Review 7.  IL-17 and IL-22: siblings, not twins.

Authors:  Stefanie Eyerich; Kilian Eyerich; Andrea Cavani; Carsten Schmidt-Weber
Journal:  Trends Immunol       Date:  2010-08-04       Impact factor: 16.687

8.  Stem cell therapies benefit Alport syndrome.

Authors:  Valerie LeBleu; Hikaru Sugimoto; Thomas M Mundel; Behzad Gerami-Naini; Elizabeth Finan; Caroline A Miller; Vincent H Gattone; Lingge Lu; Charles F Shield; Judah Folkman; Raghu Kalluri
Journal:  J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 10.121

9.  Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease.

Authors:  Alan M Hanash; Jarrod A Dudakov; Guoqiang Hua; Margaret H O'Connor; Lauren F Young; Natalie V Singer; Mallory L West; Robert R Jenq; Amanda M Holland; Lucy W Kappel; Arnab Ghosh; Jennifer J Tsai; Uttam K Rao; Nury L Yim; Odette M Smith; Enrico Velardi; Elena B Hawryluk; George F Murphy; Chen Liu; Lynette A Fouser; Richard Kolesnick; Bruce R Blazar; Marcel R M van den Brink
Journal:  Immunity       Date:  2012-08-24       Impact factor: 31.745

10.  Stromal cells protect against acute tubular injury via an endocrine effect.

Authors:  Baoyuan Bi; Roland Schmitt; Malika Israilova; Hitoshi Nishio; Lloyd G Cantley
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

View more
  2 in total

Review 1.  Mesenchymal stem cells and extracellular vesicles in therapy against kidney diseases.

Authors:  Yuling Huang; Lina Yang
Journal:  Stem Cell Res Ther       Date:  2021-03-31       Impact factor: 6.832

2.  Mesenchymal stem cells transfected with anti-miRNA-204-3p inhibit acute rejection after heart transplantation by targeting C-X-C motif chemokine receptor 4 (CXCR4) in vitro.

Authors:  Lei Tuo; Hao Song; Detian Jiang; Xiao Bai; Guangmin Song
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.